Angry and Unafraid, 'DREAMers' Denounce Trump's Decision to End DACA

07 Septembre, 2017, 19:07 | Auteur: Gerard Affre
  • The Republican National Committee is criticizing President Barack Obama hours before he headlines three fundraisers in New York City on Thursday

"I'd like to see a permanent deal and I think it's going to happen", Trump said.

"The consequence of the President's animus-driven decision is that approximately 800,000 persons who have availed themselves of the program will ultimately lose its protections and will be exposed to removal when their authorizations expire and they cannot seek renewal", the lawsuit read.

Nine states led by Texas threatened to go to court by Sept. 5 to force President Donald Trump to end the "unconstitutional" Obama program, and were likely to win.

We take a look at how DACA impacts both the U.S. economy and higher education and ask whether being a "nation of laws" trumps America's history as a nation of immigrants.

- New York joined 14 other states and the District of Columbia in a lawsuit against the federal government to protect the Deferred Action for Childhood Arrivals program, known as DACA.

This is the first time the former President publically criticizes his successor, even after he tried to dismantle his legacy Obamacare bill.

"The deserve our respect as equals and a solution rooted in American values". "It's a political decision, and a moral question", Obama said in a post on Facebook. It's up to Congress now to give these youngsters a fresh start in the land of opportunity. "Vital to our country, Dreamers are hard-working people with families who bring a diverse background that makes our country richer in every way". But on the DACA issue, the proper course for Congress is clear.

But GOP Congressional leaders said they weren't about to rush the legislation despite the veiled threats from the White House.

An open letter to Trump penned by Decibel Therapeutics CEO Steven Holtzman and Ovid Therapeutics (OVID) CEO Jeremy Levin says that DACA participants, often dubbed "Dreamers", are key players in the life sciences sector.